Project Grant R21CA316284
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $432K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
- The National Cancer Institute awarded Albert Einstein College of Medicine $431,970 on June 24, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research on Listeria-based immunotherapy targeting glioblastoma in mice. The research characterizes tumor-targeted delivery of tetanus toxoid by Listeria as a treatment approach for glioblastoma multiforme, a highly aggressive brain cancer resistant to conventional therapy. The project addresses the blood-brain barrier challenge...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded Albert Einstein College of Medicine $431,970 under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, to investigate combination approaches to acute myeloid leukemia targeting both CD123-directed NK cell engagers and BCL-2 inhibition through venetoclax. The research will employ dynamic BH3 profiling to probe mitochondrial priming mechanisms and test whether...
- The National Cancer Institute awarded Albert Einstein College of Medicine $687,291 on July 1, 2026, to fund research linking cancer driver mutations to regulatory T cell immunosuppression under the Cancer Biology Research program (CFDA 93.396). The research investigates how oncogenic mutations in aggressive breast tumors directly suppress antitumor immune responses, with particular focus on MLL3 inactivation in combination with PI3KCA activation and P53 inactivation—mutations that collectively...
- The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai $683,256 on May 22, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop and validate a human-mouse platform for patient stratification and therapeutic target discovery in glioblastoma. The recipient will integrate single-cell RNA-sequencing data from 199 glioblastoma patients with spatial transcriptomics technologies to dissect tumor microenvironment cell composition, spatial tissue organization,...
- The National Institutes of Health National Cancer Institute awarded Albert Einstein College of Medicine $695,154 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate inter-individual phenotypes of cancer gene mutation susceptibility in the human airway. The award funds research defining how somatic mutations accumulate differently across individuals in lung cancer-relevant genes, with focus on early-stage driver mutations in normal bronchial...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded The Trustees of Columbia University in the City of New York $702,132 on June 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct multiplex single-cell chemical genomics screening aimed at identifying small molecule modulators of tumor cell-intrinsic immunogenicity in glioblastoma. The research program will expose glioblastoma neurosphere models to 3,792 small...
- The National Institutes of Health National Cancer Institute awarded Albert Einstein College of Medicine $442,187 on July 15, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate how physical constriction influences cancer stem cell induction during metastasis. The research combines fluorescent biosensors for stemness with microfabricated microfluidic in vitro assays and intravital imaging of live murine lung to study the role of physical forces—including physical...
- The National Institutes of Health National Cancer Institute awarded Albert Einstein College of Medicine $431,970 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to refine and validate an MRI-based imaging technique for detecting tumor microenvironment of metastasis (TMEM) doorways in breast cancer. The award funds development of TMEM doorway activity-MRI (TDAM), a dynamic contrast-enhanced MRI method designed to measure vascular opening events...
- The National Cancer Institute awarded Cold Spring Harbor Laboratory $675,617 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate intercellular metabolic and signaling mechanisms of brain cancer-glia communication driving glioblastoma progression. The project examines how glioblastoma cells reprogram brain microglia—the brain's resident immune cells—to create an immunosuppressive tumor microenvironment that promotes tumor growth. The research focuses on an...
- The National Cancer Institute awarded Albert Einstein College of Medicine $2.038 million on August 26, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate mechanisms of early breast cancer local and distant relapse. The award supports a Project Grant (P01CA295557) with a period of performance through July 31, 2031, and place of performance in Bronx, New York. The research examines how disseminated cancer cells remain dormant in new tissue microenvironments and...